DENVER, Colo. (247marketnews.com) -- Gossamer Bio (NASDAQ:GOSS) is putting serious money behind a high-stakes regulatory bet. The company announced a structured private placement that could deliver up to $250 million, including $150 million of committed capital, as Gossamer races toward a planned September 2026 FDA submission for seralutinib in pulmonary arterial hypertension (PAH). The structure is milestone-driven: roughly $25 million is expected at the initial closing, another $125 million becomes available if the FDA accepts the NDA in 2026, and warrants could provide up to another $100 million if seralutinib ultimately receives FDA approval.
The timing is crucial. Gossamer recently reacquired worldwide development and commercial rights to seralutinib from Chiesi, giving the company substantially greater control over the program's economics and future commercialization strategy. In July, Gossamer said a pre-NDA Type B meeting with the FDA and subsequent meeting minutes provided a path toward the September NDA submission. The company said the FDA characterized questions surrounding the statistical significance and magnitude of the Phase 3 PROSERA treatment effect as “review issues rather than filing issues.” If the NDA is accepted, Gossamer says seralutinib could potentially receive an FDA decision in the third quarter of 2027.
But this is hardly a risk-free regulatory story. The Phase 3 PROSERA trial did not meet its prespecified primary statistical threshold: seralutinib produced a placebo-adjusted improvement of 13.3 meters in six-minute walk distance at Week 24, with a p-value of 0.0320 versus the prespecified alpha of 0.025. Gossamer has nevertheless pointed to supportive evidence, including a prespecified intermediate/high-risk subgroup showing a 20-meter placebo-adjusted improvement and favorable results across key secondary measures. The FDA will ultimately determine whether the totality of evidence supports approval.
That makes the financing structure particularly revealing. Gossamer isn't simply raising cash and hoping for the best; the capital is deliberately tied to regulatory milestones. CEO Faheem Hasnain said the financing is “expected to provide the capital needed to advance seralutinib through potential FDA approval in PAH,” while emphasizing that the structure aligns capital availability with key regulatory events. Gossamer reported $57 million in cash, cash equivalents and marketable securities as of June 30, 2026, meaning the new financing materially changes the company's financial runway as it approaches the NDA.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.
